Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioAtla LLC

www.bioatla.com

Latest From BioAtla LLC

Venture Funding Deals, February 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, January 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.

BioPharmaceutical Medical Device

BioAtla Building China Antibody Ops As It Eyes IPO

BioAtla has entered a strategic and option agreement with Pfizer to develop a new class of antibody therapeutics, and plans to continue working with BioDuro as part of its R&D plans and efforts in China, which include a manufacturing site in Hefei. Meanwhile, BioAtla is also eyeing a possible IPO on Nasdaq next year.

BioPharmaceutical China

Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics

ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioAtla LLC
  • Senior Management
  • Jay M Short, PhD, Chmn., Pres. & CEO
    Richard A Waldron, CFO
    Michael Melnick, PhD, VP, Bus. Dev.
    William Boyle, PhD, VP, Translational Med.
    Cathy Chang, PhD, VP, R&D, Asia
  • Contact Info
  • BioAtla LLC
    Phone: (858) 558-0708
    11011 Torreyana Rd.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register